Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study

被引：3
|
作者：
Groen, Kaz
Stege, Claudia A. M.
Nasserinejad, Kazem
de Heer, Koen
Van Kampen, Roel J. W.
Leijs, Maria B. L.
Thielen, Noortje
Westerman, Matthijs
Wu, Ka Lung
Ludwig, Inge
Issa, Djamila
Velders, Gerjo A.
Vekemans, Marie-Christiane
van de Donk, Niels W. C. J.
Timmers, Gert-Jan
Sonneveld, Pieter
Seefat, Maarten R.
Croon-de Boer, Fransien
Tick, Lidwine W.
van der Spek, Ellen
De Waal, Esther G. M.
Sohne, Maaike
Ypma, Paula F.
Nijhof, Inger S.
Klein, Saskia K.
Levin, Mark-David
Zweegman, Sonja
机构：
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-152112
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
80
引用
收藏
页数：5
相关论文
共 50 条
  • [21] Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13
    Groen, Kazimierz
    Schjesvold, Fredrik H.
    van der Holt, Bronno
    Levin, Mark-David
    Seefat, Maarten R.
    Hansson, Markus
    Leys, Maria B. L.
    Regelink, Josien C.
    Waage, Anders
    Szatkowski, Damian
    Axelsson, Per
    Hieu Do, Trung
    Svirskaite, Asta
    van der Spek, Ellen
    Haukas, Einar
    Knut-Bojanowska, Dorota
    Ypma, Paula F.
    Blimark, Cecilie H.
    Mellqvist, Ulf-Henrik
    van de Donk, Niels W. C. J.
    Sonneveld, Pieter
    Klostergaard, Anja
    Vangsted, Annette J.
    Abildgaard, Niels
    Zweegman, Sonja
    HEMASPHERE, 2023, 7 (09):
  • [22] Initial Results of a Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in Newly Diagnosed and Previously Treated AL Amyloidosis
    Lee, Hans C.
    Kaufman, Gregory P.
    Feng, Lei
    Murga, Astrid
    Johnson, Ralph J.
    Weber, Donna M.
    Thomas, Sheeba K.
    Bashir, Qaiser
    Qazilbash, Muzaffar H.
    Iyer, Swaminathan P.
    Patel, Krina
    Becnel, Melody R.
    Manasanch, Elisabet E.
    Orlowski, Robert Z.
    BLOOD, 2022, 140 : 4428 - 4430
  • [23] Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Early Relapsed/ Refractory Multiple Myeloma
    Kumar, Anupama
    Rosenberg, Aaron S.
    Padilla, Michelle
    Shah, Nina
    Sirianni, Lindsey
    Liu, Lin
    Cheng, Yuwei
    Pittman, Emily
    Tzachanis, Dimitrios
    Larson, Sarah
    Mulroney, Carolyn
    Ball, Edward D.
    Costello, Caitlin
    BLOOD, 2022, 140 : 4436 - 4437
  • [24] A Phase 2 Study of Extended Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma
    Derman, Ben A.
    Major, Ajay
    Rosenblatt, Jacalyn
    Avigan, David
    Rampurwala, Murtuza M.
    Alcantar, Luis
    Libao, Bernadette M.
    McIver, Amanda
    Andreatos, Evangelia
    Major, Sarah
    Wolfe, Brittany
    Gorski, Martha
    Karrison, Theodore G.
    Stefka, Andrew
    Jakubowiak, Andrzej
    BLOOD, 2021, 138
  • [25] Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma
    Larocca, Alessandra
    Bonello, Francesca
    Gaidano, Gianluca
    D'Agostino, Mattia
    Offidani, Massimo
    Cascavilla, Nicola
    Capra, Andrea
    Benevolo, Giulia
    Tosi, Patrizia
    Galli, Monica
    Marasca, Roberto
    Giuliani, Nicola
    Bernardini, Annalisa
    Antonioli, Elisabetta
    Rota-Scalabrini, Delia
    Cellini, Claudia
    Pompa, Alessandra
    Monaco, Federico
    Patriarca, Francesca
    di Toritto, Tommaso Caravita
    Corradini, Paolo
    Tacchetti, Paola
    Boccadoro, Mario
    Bringhen, Sara
    BLOOD, 2021, 137 (22) : 3027 - 3036
  • [26] Phase II study of carfilzomib, thalidomide, and low-dose dexamethasone as induction and consolidation in newly diagnosed, transplant eligible patients with multiple myeloma; the Carthadex trial
    Wester, Ruth
    van der Holt, Bronno
    Asselbergs, Emelie
    Zweegman, Sonja
    Kersten, Marie Jose
    Vellenga, Edo
    Kooy, Marinus van Marwijk
    de Weerdt, Okke
    Minnema, Monique
    Lonergan, Sarah
    Palumbo, Antonio
    Lokhorst, Henk
    Broijl, Annemiek
    Sonneveld, Pieter
    HAEMATOLOGICA, 2019, 104 (11) : 2265 - 2273
  • [27] Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)
    Bhutani, Manisha
    Robinson, Myra
    Paul, Barry
    Atrash, Shebli
    Varga, Cindy
    Begic, Xhevahire
    Foureau, David M.
    Pineda-Roman, Mauricio
    Koya, Brinda
    Norek, Sarah
    Sutton, Sara A.
    Anderson, Michelle B.
    Acampora, Donna
    Symanowski, James T.
    Voorhees, Peter M.
    Usmani, Saad
    BLOOD, 2022, 140 : 4440 - 4441
  • [28] Response-Adaptive Phase II Study of Daratumumab Combined with Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma
    Bhutani, Manisha
    House, Monika
    He, Jiaxian
    Atrash, Shebli
    Foureau, David M.
    Paul, Barry
    Friend, Reed
    Symanowski, James T.
    Norek, Sarah
    Begic, Xhevahire
    Acampora, Donna
    Farmer, Katherine K.
    Syfert, Carrie Ann
    Pineda-Roman, Mauricio
    Voorhees, Peter
    Usmani, Saad Z.
    BLOOD, 2020, 136
  • [29] Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study
    Harousseau, Jean-Luc
    Attal, Michel
    Leleu, Xavier
    Troncy, Jacques
    Pegourie, Brigitte
    Stoppa, Anne-Marie
    Hulin, Cyrille
    Benboubker, Lofti
    Fuzibet, Jean-Gabriel
    Renaud, Marc
    Moreau, Philippe
    Avet-Loiseau, Herve
    HAEMATOLOGICA, 2006, 91 (11) : 1498 - 1505
  • [30] Response and survival outcomes of daratumumab, lenalidomide, bortezomib and dexamethasone (D-RVD) induction in transplant-eligible newly diagnosed multiple myeloma (NDMM) patients
    Joseph, Nisha
    Kaufman, Jonathan
    Lonial, Sagar
    Hofmeister, Craig
    Dhodapkar, Madhav
    Gupta, Vikas
    DiCamillo, Sara
    Roberts, Danielle
    Boise, Lawrence
    Nooka, Ajay
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S113 - S113
12345